From Dealroom · · 40s
Alteogen Secures $149M Investment
Korean biotech Alteogen lands $149M convertible funding from state-backed investors to expand manufacturing and license drug technologies.
In brief
Korean biotech Alteogen lands $149M convertible funding from state-backed investors to expand manufacturing and license drug technologies. Alteogen secured $149M from South Korea's National Growth Fund and Skylake Equity Partners to build facilities and acquire drug tech for global licensing deals. Originally reported…
Alteogen Raises $167.7M
Alteogen secured $167.7 million through a post-IPO convertible issuance backed by South Korea's National Growth Fund and Skylake Equity Partners.
Investment Structure
The round splits into $83.8 million of convertible preferred stock and $83.8 million of redeemable convertible preferred stock.
Global Drug Licensing
Alteogen's ALT-B4 platform licenses drugs with 10 global companies including MSD, AstraZeneca, Sanofi, Novartis, and GSK.
The one thing
Alteogen secured $149M from South Korea's National Growth Fund and Skylake Equity Partners to build facilities and acquire drug tech for global licensing deals.
